Spruce Biosciences Stock Performance

SPRB Stock  USD 0.39  0.01  2.63%   
The entity has a beta of 0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Spruce Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Spruce Biosciences is expected to be smaller as well. At this point, Spruce Biosciences has a negative expected return of -0.45%. Please make sure to validate Spruce Biosciences' kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Spruce Biosciences performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Spruce Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
JavaScript chart by amCharts 3.21.15123456789Dec2025Feb -20-10010
JavaScript chart by amCharts 3.21.15Spruce Biosciences Spruce Biosciences Dividend Benchmark Dow Jones Industrial
1
Spruce Biosciences stock holds potential as Oppenheimer targets upcoming Phase 2b results
12/02/2024
2
Disposition of 128020 shares by Szwarcberg Javier B. of Spruce Biosciences at 0.537 subject to Rule 16b-3
12/10/2024
3
Oppenheimer cuts Spruce Biosciences to perform
12/11/2024
4
Disposition of 111000 shares by Szwarcberg Javier B. of Spruce Biosciences subject to Rule 16b-3
12/16/2024
5
Disposition of 32005 shares by Szwarcberg Javier B. of Spruce Biosciences at 0.3887 subject to Rule 16b-3
12/20/2024
6
Spruce Biosciences Appoints Interim Chief Medical Officer - TipRanks
12/27/2024
7
Spruce Biosciences, Inc. Receives 3.90 Consensus Target Price from Brokerages
12/31/2024
8
Acquisition by Gharib Samir M. of 308000 shares of Spruce Biosciences subject to Rule 16b-3
01/17/2025
9
NeoGenomics Tops Q4 Earnings Estimates
02/18/2025
Begin Period Cash Flow24.7 M
  

Spruce Biosciences Relative Risk vs. Return Landscape

If you would invest  54.00  in Spruce Biosciences on December 3, 2024 and sell it today you would lose (15.00) from holding Spruce Biosciences or give up 27.78% of portfolio value over 90 days. Spruce Biosciences is currently does not generate positive expected returns and assumes 4.2266% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Spruce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketSPRB 01234 -0.5-0.4-0.3-0.2-0.10.0
       Risk  
Given the investment horizon of 90 days Spruce Biosciences is expected to under-perform the market. In addition to that, the company is 5.63 times more volatile than its market benchmark. It trades about -0.11 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.04 per unit of volatility.

Spruce Biosciences Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Spruce Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Spruce Biosciences, and traders can use it to determine the average amount a Spruce Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1059

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsSPRB

Estimated Market Risk

 4.23
  actual daily
37
63% of assets are more volatile

Expected Return

 -0.45
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.11
  actual daily
0
Most of other assets perform better
Based on monthly moving average Spruce Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Spruce Biosciences by adding Spruce Biosciences to a well-diversified portfolio.

Spruce Biosciences Fundamentals Growth

Spruce Stock prices reflect investors' perceptions of the future prospects and financial health of Spruce Biosciences, and Spruce Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spruce Stock performance.
Return On Equity-0.58
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%-150%-100%-50%
Return On Asset-0.3
Operating Margin(15.63) %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-10%-8%-6%-4%-2%
Current Valuation(40.99 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Shares Outstanding41.3 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%
Price To Book0.31 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-150%-100%-50%0%50%100%150%
Price To Sales2.26 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-20%-15%-10%-5%
Revenue10.09 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Gross Profit(28.96 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150,000%100,000%150,000%200,000%250,000%300,000%
EBITDA(47.37 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Net Income(47.92 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Cash And Equivalents93.3 M
Cash Per Share3.96 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%200%400%600%
Total Debt4.61 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315%10%15%20%25%30%35%
Debt To Equity0.07 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-150%-100%-50%
Current Ratio9.55 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%200%400%600%800%
Book Value Per Share1.25 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-250%-200%-150%-100%-50%
Cash Flow From Operations(33.27 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-3150%100%150%200%250%300%350%
Earnings Per Share(0.95) X
Market Capitalization16.07 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-80%-60%-40%-20%
Total Asset103.95 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%2,500%3,000%
Retained Earnings(197.23 M)
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31200%400%600%800%
Working Capital77.72 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31

About Spruce Biosciences Performance

By analyzing Spruce Biosciences' fundamental ratios, stakeholders can gain valuable insights into Spruce Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Spruce Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Spruce Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.41)(0.44)
Return On Capital Employed(0.59)(0.62)
Return On Assets(0.41)(0.44)
Return On Equity(0.72)(0.68)

Things to note about Spruce Biosciences performance evaluation

Checking the ongoing alerts about Spruce Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spruce Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Spruce Biosciences generated a negative expected return over the last 90 days
Spruce Biosciences has some characteristics of a very speculative penny stock
Spruce Biosciences has high historical volatility and very poor performance
Spruce Biosciences has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (47.92 M) with loss before overhead, payroll, taxes, and interest of (28.96 M).
Spruce Biosciences currently holds about 93.3 M in cash with (33.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Spruce Biosciences has a frail financial position based on the latest SEC disclosures
Latest headline from zacks.com: NeoGenomics Tops Q4 Earnings Estimates
Evaluating Spruce Biosciences' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Spruce Biosciences' stock performance include:
  • Analyzing Spruce Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spruce Biosciences' stock is overvalued or undervalued compared to its peers.
  • Examining Spruce Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Spruce Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spruce Biosciences' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Spruce Biosciences' stock. These opinions can provide insight into Spruce Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Spruce Biosciences' stock performance is not an exact science, and many factors can impact Spruce Biosciences' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Spruce Stock analysis

When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance